A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients
暂无分享,去创建一个
[1] J. Murray,et al. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy , 2002, British Journal of Cancer.
[2] Le Zhang,et al. Multi-scale, multi-resolution brain cancer modeling , 2008, Math. Comput. Simul..
[3] Maciej Swat,et al. Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. , 2015, Seminars in cancer biology.
[4] Frank Thiele,et al. Clinical Evaluation of a Multiparametric Deep Learning Model for Glioblastoma Segmentation Using Heterogeneous Magnetic Resonance Imaging Data From Clinical Routine , 2018, Investigative radiology.
[5] Gustavo Marrero Callicó,et al. Deep Learning-Based Framework for In Vivo Identification of Glioblastoma Tumor using Hyperspectral Images of Human Brain , 2019, Sensors.
[6] Kristin R. Swanson,et al. Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma , 2013, PloS one.
[7] Salvatore Torquato,et al. Modeling the effects of vasculature evolution on early brain tumor growth. , 2006, Journal of theoretical biology.
[8] Jennie W. Taylor,et al. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. , 2015, Neurosurgery.
[9] Luigi Fortuna,et al. M. L. P. Optimal Topology via Genetic Algorithms , 1993 .
[10] W. Mason,et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[12] H Paganetti,et al. Methodologies in the modeling of combined chemo-radiation treatments , 2016, Physics in medicine and biology.
[13] L. Deangelis,et al. A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM) , 2007 .
[14] Jeffrey Pennington,et al. Semi-Supervised Recursive Autoencoders for Predicting Sentiment Distributions , 2011, EMNLP.
[15] Max Kuhn,et al. Applied Predictive Modeling , 2013 .
[16] Blair Jarvis,et al. Temozolomide A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers , 2002 .
[17] C. Davatzikos,et al. Survival Analysis of Patients with High-Grade Gliomas Based on Data Mining of Imaging Variables , 2012, American Journal of Neuroradiology.
[18] Katrina H. Smith,et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. , 2013, Neuro-oncology.
[19] Peter T. Nelson,et al. Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors , 2004, Clinical Cancer Research.
[20] R. Sridhar,et al. Cytotoxicity of glucose analogues in V79 multicell spheroids , 1979, In Vitro.
[21] Xiaobo Zhou,et al. Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis , 2012, BMC Bioinformatics.
[22] Amy Loutfi,et al. A review of unsupervised feature learning and deep learning for time-series modeling , 2014, Pattern Recognit. Lett..
[23] D. Misailidou,et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Luke Macyszyn,et al. Imaging patterns predict patient survival and molecular subtype in glioblastoma via machine learning techniques. , 2016, Neuro-oncology.
[25] M. M. Lotfi,et al. A modified NSGA-II solution for a new multi-objective hub maximal covering problem under uncertain shipments , 2014 .
[26] E. Kostelich,et al. Virtual glioblastoma: growth, migration and treatment in a three‐dimensional mathematical model , 2009, Cell proliferation.
[27] Ciprian Catana,et al. Multimodality imaging and mathematical modelling of drug delivery to glioblastomas , 2016, Interface Focus.
[28] J. Kirkwood,et al. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. , 2000, The oncologist.
[29] Abbas Ahmadi,et al. Simulation-based optimization of radiotherapy: Agent-based modeling and reinforcement learning , 2017, Math. Comput. Simul..
[30] R. Stupp,et al. The Role of Radio- and Chemotherapy in Glioblastoma , 2005, Oncology Research and Treatment.
[31] Frederik Barkhof,et al. Robust Deep Learning–based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training , 2020, Radiology. Artificial intelligence.
[32] S. Baruchel,et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. , 2006, European journal of cancer.
[33] R. Peck. Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient. , 2018, Annual review of pharmacology and toxicology.
[34] K. Aldape,et al. Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.
[35] R. Roy. A Primer on the Taguchi Method , 1990 .
[36] Mark R Gilbert,et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Vittorio Cristini,et al. Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. , 2012, Journal of theoretical biology.
[38] Davide Anguita,et al. The 'K' in K-fold Cross Validation , 2012, ESANN.
[39] Kalyanmoy Deb,et al. A Comparative Analysis of Selection Schemes Used in Genetic Algorithms , 1990, FOGA.
[40] A. Unterberg,et al. Factors triggering an additional resection and determining residual tumor volume on intraoperative MRI: analysis from a prospective single-center registry of supratentorial gliomas. , 2016, Neurosurgical focus.
[41] T van Doorn,et al. Tumour resistance to cisplatin: a modelling approach , 2005, Physics in medicine and biology.
[42] Haruna Chiroma,et al. Neural networks optimization through genetic algorithm searches: A review , 2017 .
[43] Dominique Barbolosi,et al. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model , 2001, Comput. Biol. Medicine.
[44] Robert A Gatenby,et al. A theoretical quantitative model for evolution of cancer chemotherapy resistance , 2010, Biology Direct.
[45] Jafar Habibi,et al. Hybrid multiscale modeling and prediction of cancer cell behavior , 2017, PloS one.
[46] Josh Harguess,et al. Generative NeuroEvolution for Deep Learning , 2013, ArXiv.
[47] Norman F. Kirkby,et al. A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. , 2010, Journal of theoretical biology.
[48] Madjid Soltani,et al. Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide , 2020, Comput. Methods Programs Biomed..
[49] Trevor Hastie,et al. An Introduction to Statistical Learning , 2013, Springer Texts in Statistics.
[50] K. Aldape,et al. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. , 2015, Neuro-oncology.
[51] Gargi Chakraborty,et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. , 2009, Cancer research.
[52] Susan M. Chang,et al. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. , 2014, Neuro-oncology.
[53] Peter A. Wallace,et al. A review on applications of genetic algorithm for artificial neural network , 2016 .
[54] Robert J. Marks,et al. Neural Smithing: Supervised Learning in Feedforward Artificial Neural Networks , 1999 .
[55] P. Bossuyt,et al. Individual patient data meta-analysis: a promising approach for evidence synthesis in reproductive medicine. , 2010, Human reproduction update.
[56] Gael Varoquaux,et al. Establishment of Best Practices for Evidence for Prediction: A Review. , 2019, JAMA psychiatry.
[57] Jana L. Gevertz,et al. Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation , 2011, Comput. Math. Methods Medicine.
[58] Vittorio Cristini,et al. Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach , 2010 .
[59] M. Walker,et al. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.
[60] B. Jeremic,et al. Short-course Radiotherapy in Elderly and Frail Patients with Glioblastoma Multiforme. A Phase II Study , 1999, Journal of Neuro-Oncology.
[61] Vittorio Maniezzo,et al. Searching among Search Spaces: Hastening the genetic evolution of feedforward neural networks , 1993 .
[62] Wei Cao,et al. Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma , 2017, Scientific Reports.
[63] Jimeng Sun,et al. Constraint based temporal event sequence mining for Glioblastoma survival prediction , 2016, J. Biomed. Informatics.
[64] Jason A. Chen,et al. Artificial Intelligence in the Management of Glioma: Era of Personalized Medicine , 2019, Front. Oncol..
[65] Risto Miikkulainen,et al. Designing neural networks through neuroevolution , 2019, Nat. Mach. Intell..
[66] L. Schad,et al. A generic support vector machine model for preoperative glioma survival associations. , 2015, Radiology.
[67] Nikolaos K. Uzunoglu,et al. A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide , 2006, IEEE Transactions on Biomedical Engineering.
[68] Teresa B Ludermir,et al. Global Optimization Methods for Designing and Training Feedforward Artificial Neural Networks , 2007 .
[69] G. Reifenberger,et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] John H. Holland,et al. Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .
[71] Yang Yang,et al. Glioma Grading on Conventional MR Images: A Deep Learning Study With Transfer Learning , 2018, Front. Neurosci..
[72] Genichi Taguchi,et al. Taguchi's Quality Engineering Handbook , 2004 .
[73] G Powathil,et al. Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy , 2007, Physics in medicine and biology.
[74] Neil G Burnet,et al. A mathematical model of the treatment and survival of patients with high-grade brain tumours. , 2007, Journal of theoretical biology.
[75] A. Brandes,et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.
[76] K. Camphausen,et al. In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide , 2008, Clinical Cancer Research.
[77] C. G. Newton,et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. , 1984, Journal of medicinal chemistry.
[78] Gary H Lyman,et al. The strengths and limitations of meta-analyses based on aggregate data , 2005, BMC Medical Research Methodology.
[79] Nicolas André,et al. Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.
[80] L. Deangelis,et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. , 2013, Neuro-oncology.
[81] Joseph D Butner,et al. Simulating cancer growth with multiscale agent-based modeling. , 2015, Seminars in cancer biology.
[82] Thomas G. Dietterich. Adaptive computation and machine learning , 1998 .
[83] J. Murray,et al. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion , 2003, Journal of the Neurological Sciences.
[84] G. Reifenberger,et al. One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma , 2007 .
[85] Gibin G Powathil,et al. Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: biological insights from a hybrid multiscale cellular automaton model. , 2012, Journal of theoretical biology.
[86] E S Newlands,et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.
[87] Václav Snásel,et al. Metaheuristic design of feedforward neural networks: A review of two decades of research , 2017, Eng. Appl. Artif. Intell..
[88] D. Raabe,et al. Hydrogen enhances strength and ductility of an equiatomic high-entropy alloy , 2017, Scientific Reports.
[89] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[90] J. Knisely,et al. Importance of hypoxia in the biology and treatment of brain tumors. , 2002, Neuroimaging clinics of North America.
[91] Zhihui Wang,et al. Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior , 2007, Biosyst..
[92] J M Wardlaw,et al. Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).
[93] Bowen Xin,et al. Machine Learning Models for Multiparametric Glioma Grading With Quantitative Result Interpretations , 2019, Front. Neurosci..
[94] S. Steinberg,et al. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. , 1994, International journal of radiation oncology, biology, physics.
[95] M. Mrugala,et al. Mechanisms of Disease: temozolomide and glioblastoma—look to the future , 2008, Nature Clinical Practice Oncology.
[96] Jafar Habibi,et al. Integrating evolutionary game theory into an agent-based model of ductal carcinoma in situ: Role of gap junctions in cancer progression , 2016, Comput. Methods Programs Biomed..
[97] E. Hall,et al. Radiobiology for the radiologist , 1973 .
[98] Paul Kinahan,et al. A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET , 2015, Journal of The Royal Society Interface.
[99] Shuang Wu,et al. Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas , 2019, Journal of Cancer Research and Clinical Oncology.